...www.pwc.com/us/pharma Aspiring giants How small pharmas can drive to $1 billion — and beyond PwC’s PRTM Management Consulting Aspiring giants Executive summary Amid the volatile blend of opportunity and challenge that characterizes the global pharmaceutical industry, only a few small companies have managed to catapult their revenue over the $1 billion mark over the past two decades. Whether they chose to expand their therapeutic area focus and product portfolios, enter new geographies, or grow their core business, these aspiring giants pursued three distinct strategies to jump-start growth: Leveraged core product and technology capabilities to launch differentiated products Used mergers and acquisitions to gain new products and/or expand geographic presence Built a strong, stable leadership team armed with a compelling vision and relentless drive The experiences of these winning companies offer lessons for today’s smaller pharma companies harboring the ambition to reach the $1 billion revenue mark. To achieve this milestone, these companies will need to excel in three areas: expanding a core area of expertise to deliver niche and valueadded products, adopting an acquisition and partnering mindset to expand product offerings and geographic presence, and attracting and retaining talented leaders. Focusing on these fronts can help position a pharma company to become a growth leader—rather than merely a follower—in tomorrow’s...
Words: 4167 - Pages: 17
...GCC Pharmaceutical Industry March 31, 2013 Alpen Capital was awarded the “Best Research House” at the Banker Middle East Industry Awards 2011 GCC Pharmaceutical Sector | March 31, 2013 Page | 2 Table of Contents 1. 1.1. 1.2. 1.3. 1.4. EXECUTIVE SUMMARY............................................................................ 6 Scope of the Report .................................................................................. 6 Key Growth Drivers .................................................................................. 6 Key Challenges ........................................................................................ 6 Trends .................................................................................................... 7 2. 2.1 2.2 2.3 2.4 2.5 2.6 2.7 GCC PHARMACEUTICAL INDUSTRY OVERVIEW ...................................... 8 GCC Pharmaceutical Market Overview ............................................................. 8 The UAE Pharmaceutical Market .................................................................... 11 The Saudi Arabian Pharmaceutical Market ...................................................... 13 The Kuwaiti Pharmaceutical Market ............................................................... 15 The Qatari Pharmaceutical Market ................................................................. 16 The Bahraini Pharmaceutical Market .............................................................. 17 The...
Words: 27542 - Pages: 111
...RESEARCH PROJECT ON “TRAINING AND DEVELOPMENT IN PHARMASUITICAL INDUSTRY WITH SPECIAL REFERENCE OF MANKIND PHARMA LTD” SUBMITTED IN PARTIAL FULFILLMENT OF DEGREE OF BACHELOR OF BUSINESS ADMINISTRATION SESSION (2011-2014) SUBMITTED TO: SUBMITTED BY: XYZ XYZ BBA III University Roll No. SUBMITTED TO ACKNOWLEGDEMENT “Gratitude is the hardest of emotions to express and one often does not find adequate words to convey what one feels and trying to express it” The present project file is an amalgamated of various thoughts and experiences .The successful completion of this project report would have not been possible without the help and guidance of number of people and specially to my project guide .I take this opportunity to thank all those who have directly and indirectly inspired, directed and helped me towards successful completion of this project report. I am also immensely indebted to my project guide, MS. Divya Vaid Lecturer, ICL, for his illumining...
Words: 8569 - Pages: 35
...Respected Sir/Madam, I xxxx completed Bachelors in xyz College of xyz affiliated to University, Mumbai with 50% Following this, I was involved in research and has been working as an Analyst for Plant pharmaceuticals in Quality Control Department of Alapati Pharma company. I was Kindled with an ambition of higher education that would give a desired push to my career. With a strong will to pursue my further studies in Canada, I prepared for the IELTS examination and scored 6.5 bands. I am prepared to further deepen and refine my expertise through Biotechnology Course which has led me to take admission in one of the top Colleges, Centennial College, Canada. I was brought up in a well educated family and this helped me to maintain a consistent and excellent academic record; I secured Distinction marks in SSC and Intermediate. During my Bachelors, I submitted many research papers in worldwide and India wide seminars like IPC, IPA, National seminars where 12 of my Research papers were published in Medical and Pharmacy Journals. I was also awarded a "Gold medal" for a Seminar conducted by Indian Pharmaceutical Congress which provided me a wonderful platform to meet the top heads of Pharmaceutical Industry in the country. I Started my career as an Asst. Manufacturing Chemist in Triomed Formulations India(Pvt) Ltd as soon as i was graduated. Then i opted for a Subject Knowledge Enhancement Course (Student...
Words: 741 - Pages: 3
...NERACA PEMBAYARAN Neraca Pembayaran (balance of payments) adalah suatu catatan dari aktifitas ekonomi yang meliputi perdagangan barang/jasa, transfer keuangan yang dilakukan antara penduduk dalam negeri dengan penduduk luar negeri selama periode waktu tertentu, biasanya selama satu tahun. Pencatatan transaksi dilakukan dengan pembukuan berpasangan(double entry bookeeping) Neraca pembayaran dapat dibagi atas beberapa komponen yaitu neraca berjalan dan neraca modal. * Neraca berjalan (current account) adalah ukuran perdagangan barang dan jasa internasional suatu negara yang paling luas, komponen utamanya adalah neraca perdagangan yaitu selisih antara ekspor dan impor. Jika ekspor lebih tinggi dari impor maka terjadi surplus, sedangkan jika impor lebih tinggi daripada ekspor maka terjadi defisit neraca perdagangan. Faktor-faktor yang mempengaruhi neraca berjalan : 1. Inflasi Jika laju inflasi sebuah negara meningkat relatif terhadap inflasi negara-negara mitra dagangnya, neraca berjalannya akan menurun. 2. Pendapatan Nasional Jika tingkat pendapatan nasional sebuah negara meningkat dengan persentase relatif lebih tinggi daripada negara lain, neraca berjalannya akan menurun. 3. Restriksi Pemerintah Biasanya pemerintah mengenakan tarif (pajak yang dikenakan ataus produk impor) dan kuota (batas maksimum atas barang yang diperbolehkan untuk diimpor ke dalam sebuah negara) untuk mempengaruhi neraca berjalan. 4. Nilai tukar (kurs) valuta Jika nilai valuta suatu negara...
Words: 688 - Pages: 3
...Impact of the economic recession on the pharmaceutical sector February 2010 I.M. Buysse (UU) Supervised by: R.O. Laing (WHO) A.K. Mantel (UU) WHO COLLABORATING CENTRE FOR PHARMACOEPIDEMIOLOGY & PHARMACEUTICAL POLICY ANALYSIS Impact of the economic recession on the pharmaceutical sector Table of contents Executive summary ................................................................................................................................. 3 Introduction ............................................................................................................................................ 6 Background ............................................................................................................................................. 8 History of recessions ............................................................................................................................................................. 8 Asian Crisis 1997-2000 .......................................................................................................................................................... 9 Economic crisis 2008-2009.................................................................................................................................................. 12 WHO involvement in assessing the impact of the recession .............................................................................................. 14 Hypotheses ...................
Words: 25253 - Pages: 102
...THE PHARMACEUTICAL MARKET: INDIA - REVIEW The Indian pharmaceutical market is highly competitive and remains dominated by low-priced, domestically-produced generics. Despite having the second largest population in the world and a growing middle class with high healthcare expectations, India accounts for less than 2% of the world pharmaceutical market in value terms. In one of the world's better performing economies, spending on pharmaceuticals accounts for less than 1% of GDP and average per capita spending remains one of the lowest levels in the region. India’s biopharmaceutical sector is currently experiencing double digit growth and this is expected to continue, driven by the vaccines market. Growth drivers include education and increased awareness of disease prevention, increases in disposable income and government participation in immunisation programmes. Continued growth is also expected in the diagnostic and therapeutic segments, including cancer and diabetes. India is already known as the diabetes capital of the world and the number of diabetes patients in India is expected to grow to 70 million by 2025. Cancer therapies are also lucrative for many Indian companies due to high unmet need, increased awareness and the comparative affordability of domestically produced drugs. The Indian pharmaceutical industry is responsible for around 10% of world pharmaceutical production. Over the last few years, a number of Indian pharmaceutical companies have been targeted...
Words: 578 - Pages: 3
...The key issue affecting the pharmaceutical industry is the ability of the pharmaceutical industry to remain profitable and returning a high rate of return that has been historically been so. The Pharmaceutical industry is an industry in which the entry barriers are very high as the companies in the business must spend a large amount of money on research. And the research may only yield results in some cases, only 3 out of 10 drugs recoup their costs and takes around $800 Million and 15 years to release a new drug. The companies that dominate the industry usually have dominant companies in that rely upon very few of their drugs for returning revenues. As a standing testimony, 55% of Pfizers revenues are generated from just 3 drugs ($28 billion dollars!). Whilst there are challenges of prices and new regulations, the industry offers new opportunities 3 Alternatives: 1) Research and Develop drugs in the areas of chronic care, Healthier living such as nutritional business. As people from the baby boom age grow wiser and start to look for ways to prolong life with the least bit of worries for reliance on healthcare, there is a shift in people moving for nutritional drugs. 2) Research and develop in the areas of preventive medicine, diagnostics, genetic testing. It’s an age long drug that cannot seem to go wrong. With the increase in awareness in people, there is an increase in their wanting to try newer things, Genetic and generic medicines being an example of that. People...
Words: 380 - Pages: 2
...UGKTVPG IPKVPWQEEC GVCKTRQTRRC GEWFQTR FPC UVPGXG UUGPKUWD GMCV QV UK IPKVPWQEEC HQ GNQT GJV VCJV IPKVCEKFPK PQQVTCE GXKVUGIIWU [NNWHGRQJ VWD UUGNIPKPCGO # GTWIK( U G K T V P G I PK V P W Q E E C G E W F Q T R Q V V P G X G P C Q V I PK V E C G T U C G T W V E K R N CV P G O C F P W H G JV G G U + G OK V PK V P K Q R U K J V V # T G JV Q J E C G Q V G V CN G T [ G JV Y Q J F P C G T C U P T G V V C R G J V V C J Y T G V V G D F P C V U T G F P W Q V F T C J F GK T V G X + U T C G [ G U Q J V T G X 1 G PK N G RK R U C I G I T CN C P K U C I M E C TV Q V O GV U [ U C I PK F NK W D U P T G VV C R G U G JV H Q N C T G X G U F G U W G P K O H Q GV CK E Q U U C G P 1 [ G P Q O G JV G V C N W RK P C O F P C M E C TV V C J V U P T GV V C R G O C U G J V J V K Y T QH F G V P W Q E E C G T C G OK V U G N R Q G R H Q U T W Q J T Q [ V K EK TV E G N G H Q U T W Q J V V C Y Q N K M G T G J Y N N Q T [ C R F P C I P K N N K D [ V K N K V W P K UK J V G G U P C E W Q ; [ G P Q O P C J V T G JV Q U I P K J V Q V [ N R R C P C E U P T G V V C R G U G J 6 [ G P Q O Q V [ N R R C V U W L V P Q F G T G J F G DK T E U G F F P C P G G U G X + U P T G V V C R G J V V W $ N N Q T [ C R F P C I P KN N K D [ V KN KV W F G F W N E P K G X C J U G N R O C Z G [ O Q 5 V P G X G G J V H Q U G E P G W S G U P Q E N C K E P C P K H G J V V W Q I PK T W I K H [ D U V P G X G U U G P K U W D Q V U F P Q R U G T V C J V O G V U [ U [ P C P C G O + T G JV C 4 GN D C [ C 2 U V P W Q...
Words: 41707 - Pages: 167
...The effect of big pharma on healthcare EN 1320 26 May 2013 The effect of big pharma on healthcare Big pharmacy has always been a hot button issue, for as long as I can remember. It is proven that the large drug companies are using unethical practices to help boost sales. These practices in turn cost the patient more at the counter in the pharmacy. This also leads to shady practices by physicians. Fortune magazine reported that in 2008, the pharmaceutical industry continued to be in the top three most profitable industries in the United States for the past two decades. Studies show that marketing strategies used by pharmaceutical representatives such as education, samples, office support, and patient resources can increase brand recognition and influence prescribing. This leads to patients being influenced to spend more money on the brand name drugs, rather than the cheaper generic versions that work exactly the same. References Insert References Here. Place the cursor at the beginning of this line, and then, on the CiteWrite menu, click Format, Write Bibliography. For more help with your references, click Start, Programs, Dr Paper, Dr Paper Help, and go through the instructions under Using CiteWrite for your References. If you just have one or two references, you might want to just type them by hand, following these examples: Hall, K. G. (2005, August 29). Web page title. Website title. Retrieved September 25, 2005, from http://www.kansas.com/mld/kansas/12506343...
Words: 276 - Pages: 2
...The Pharmaceutical industry in the Global Economy Summer 2005 Larry Davidson* and Gennadiy Greblov Indiana University Kelley School of Business Bloomington, Indiana *Davidson is Professor of Business Economics and Public Policy and Greblov is working towards his MBA degree at the Kelley School of Business Prepared for the Indiana Economic Development Corporation with the support of the Center for International Business Education and Research at the Indiana University Kelley School of Business. Information Services via the World Trade Atlas, U.S. State Export Edition. To receive free copies of the export report please contact the Indiana Economic Development Corporation’s Office of International Trade at 317.232.4949. Direct questions to the authors of the report to Larry Davidson at davidso@indiana.edu or 812.855.2773. Introduction This paper summarizes the results of our global pharmaceutical industry analysis and is intended to increase awareness of the general public – investors, policy makers, managers, employees of the companies – about its current developments. The paper has the following major goals: 1) To analyze the current situation, major challenges and the prospects of the pharmaceutical industry; 2) To identify major players of the global pharmaceutical industry and make a comparative analysis of their business practices and financial results; 3) To determine the relative position of the U.S. pharmaceutical...
Words: 10094 - Pages: 41
...www.pwc.com/pharma2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Pharmaceuticals Pharma 2020: The vision Which path will you take?* Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. Pharmaceuticals and Life Sciences Pharma 2020: Challenging business models Which path will you take? Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. *connectedthinking Pharma 2020: The vision # Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take? This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and providers...
Words: 13197 - Pages: 53
...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be an indepth discussion...
Words: 5468 - Pages: 22
...INDIAN PHARMACEUTICAL INDUSTRY – AN OVERVIEW 1. Overview The Indian Pharma industry is one of the fastest growing sectors with approximately 20,000 manufacturing units. The industry that is highly price sensitive ranks thirteenth in the global pharmaceutical market in value terms and fourth in volume terms. The country has tremendous export potential in the areas like custom synthesis, R&D, clinical trials, and Bioinformatics. The industry produces 60,000 finished medicines and roughly 400 bulk drugs, which are used in formulations with about 20% of the manufacturers in the bulk drugs segment. India has approximately 1% share of global pharma industry, which is worth US$406 billion. This implies that there is a huge market waiting to be unfolded. The figure below explains the evolution of Indian pharmaceutical industry: Figure 1: Progress Of Indian Pharmaceutical Industry Source: Pharmabiz.com (Article by Dr. Laxman Prasad) 2. Industry Structure and Size 2.1 Industry Structure The Indian Pharma industry is highly fragmented and can broadly be classified in to two categories: organized and unorganized sector. Figure 2: Revenues of Organised vs. Unorganised Sector Source: Secondary Research The organized sector contributes about 70% of the total revenues and consists of 260 units in both manufacturing as well as formulation segment. This sector can further be divided into Indian and multinational companies. The unorganized sector is...
Words: 1530 - Pages: 7
...technology, quality and range of medicines manufactured. From simple headache pills to sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units approved by regulatory authorities in USA and UK. International companies associated with this sector have stimulated, assisted and spearheaded this dynamic development in the past 53 years and helped to put India on the pharmaceutical map of the world. Growth Scenario in 2010 India's pharmaceutical industry is now the third largest in the world in terms of volume. Its rank is 14th in terms of value. Between September 2008 and September 2009, the total turnover of India's pharmaceuticals industry was US$ 21.04 billion. The domestic market was worth US$ 12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$ 10.04 billion in size in July 2010. A highly organized sector, the Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually. Know more out this in our article on Indian Pharmaceutical Industry- Future Trends Also check out Pharmaceutical Market Trends 2010 Leading...
Words: 1244 - Pages: 5
